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OBJECTIVE: To determine whether curcumin reverses the multidrug resistance of human colon cancer cells in
vitro and in vivo.
METHODS: In a vincristine-resistant cell line of human colon cancer, the cell viability of curcumin-treated cells
was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Rhodamine123
efflux was evaluated to detect P-glycoprotein transporter activity, and expression of the multidrug resistance
protein 1 and survivin genes was analyzed by reverse transcription polymerase chain reaction and western
blotting. In addition, xenograft mouse tumors were grown and treated with curcumin. The morphology of the
xenografts was investigated by hematoxylin-eosin staining. The in vivo expression of the multidrug resistance
gene and P-glycoprotein and survivin genes and proteins was observed using reverse transcription-polymerase
chain reaction and western blotting, respectively.
RESULTS: Curcuminwas not obviously toxic to the vincristine-resistant human colon cancer cells at concentrations
less than 25 mM, but the growth of cells was significantly inhibited. At concentrations greater than 25 mM,
curcumin was toxic in a concentration-dependent manner. The sensitivity of cells to vincristine, cisplatin,
fluorouracil, and hydroxycamptothecin was enhanced, intracellular Rhodamine123 accumulation was increased
(p,0.05), and the expression of the multidrug resistance gene and P-glycoprotein were significantly suppressed
(p,0.05). The combination of curcumin and vincristine significantly inhibited xenograft growth. The expression
of the multidrug resistance protein 1 and survivin genes was significantly reduced in xenografts of curcumin-
treated mice and mice treated with both curcumin and vincristine relative to control mice.
CONCLUSION: Curcumin has strong reversal effects on themultidrug resistance of human colon carcinoma in vitro
and in vivo.
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& INTRODUCTION
Colon cancer is the third leading cause of cancer death in
the USA, and the incidence is rapidly increasing in
developing countries, including China (1). Chemotherapy
plays an important role in the management of patients with
colon carcinoma (2). Multidrug resistance (MDR) is one of
the main impediments to the successful treatment of colon
cancer (3) and consists of simultaneous resistance to many
structurally unrelated cytotoxic agents (4). MDR in tumors
involves different mechanisms, and a commonmechanism of
MDR is the active export of the drug from cells by the
overexpression of P-glycoprotein (P-gp) (5) and other ATP-
binding cassette (ABC) transporters. P-gp plays an important
role in mediating resistance to apoptosis, which is important
for MDR (6). Recently, resistance to chemotherapy has been
associated with the inhibition of apoptosis. Induction of
apoptosis can reverse the MDR of colon cancer (7). Agents
that effectively reverse MDR are highly desirable.
Curcumin is a natural phenolic yellow-colored compound
that is found in the plant Curcuma longa and has a wide
range of biological and pharmacological activities, including
antioxidant and anti-inflammatory properties, anti-muta-
genic activity, and anti-carcinogenic, hypocholesterolemic,
and hypoglycemic effects (8). In vitro studies have demon-
strated that curcumin can overcome MDR in many tumors
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(9). However, it is not known whether curcumin can reverse
the MDR of colon cancer cells, which led us to evaluate the
effect of curcumin on the MDR of cancer cells.
In the present work, we investigated the effect of
curcumin on vincristine resistance in the human colon
cancer cell line HCT-8/VCR in vitro and in vivo and the
mechanisms underlying this effect. We found that co-
treatment of HCT-8/VCR cells with curcumin increased
their sensitivity to vincristine (VCR), cisplatin (DDP),
fluorouracil (5-FU), and hydroxycamptothecin (HCPT).
Curcumin decreased the expression of P-gp and survivin
and enhanced the accumulation of intracellular rhoda-
mine123 (Rh123) in HCT-8/VCR cells. The combination of
curcumin and VCR in vivo significantly inhibited xenograft
growth, decreased tumor weight, and increased tumor cell
apoptosis. Our results suggest that curcumin can reverse the
MDR of colon cancer in vitro and in vivo. Curcumin could
thus be useful in the treatment of MDR in human colon
cancer cells as a MDR modulator.
& MATERIALS AND METHODS
Reagents
Curcumin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT), ethidium bromide, acridine orange
(AO), and rhodamine123 (Rh123) were obtained from Sigma
(St. Louis, MO, USA); vincristine (VCR), hydroxycamp-
tothecin (HCPT), cisplatin (DDP), and fluorouracil (5-FU)
were obtained from Shenzhen Main Luck Pharmaceuticals
Inc. (Shenzhen, China); P-gp and survivin antibodies and
HRP-conjugated goat anti-rabbit IgG were purchased from
Biosynthesis Biotechnology (Beijing, China); Trizol, the
reverse transcription-polymerase chain reaction (RT-PCR)
kit, and the western blot kit were purchased from Takara
Biotechnology Co., Ltd. (Dalian, China).
Cell lines and cell culture
The vincristine-resistant human colon cancer cell line HCT-
8/VCR was obtained from the Shanghai Cell Collection
(Shanghai, China). The cells were routinely cultured in
RMPI-1640 supplemented with 10% heat-inactivated fetal
bovine serum (Gibco), 100 IU/ml penicillin, and 100 IU/ml
streptomycin at 37 C˚ in a 5% CO2 atmosphere. The medium
for HCT-8/VCR cells was further supplemented with 2 mg/
ml VCR. The HCT-8/VCR cells were cultured in drug-free
medium for 1 week prior to use in experiments.
Determination of curcumin concentration
Cells were seeded in 96-well plates at a density of 56103
HCT-8/VCR cells per well and incubated in a humidified
atmosphere of 5% CO2 and 95% air overnight. Then, 6.25,
12.5, 25, 50, or 100 mM curcumin (20 ml) was added. After
incubation for 48 h, 20 ml of MTT (5 g/L) was added. The
plates were incubated for 4 h, and the blue dye formed was
dissolved in 100 ml of dimethyl sulfoxide (DMSO). The
absorbance at 570 nm was recorded using a microplate
reader, and the inhibition rate was calculated.
Cell viability assay
Cells were seeded in 96-well plates at a density of 36103
cells per well and cultured for 24 h before treatment with
6.25, 12.5, or 25 mM curcumin and 0.5 mg/ml VCR (20 ml).
After the indicated incubation time, 20 ml of MTT [5 mg/ml
in phosphate-buffered saline (PBS)] was added to each well,
and the cells were incubated for an additional 4 h at 37 C˚.
Finally, 150 ml of DMSO was added to stop the reaction. The
absorbance at 570 nm was measured to determine the cell
viability in each well.
Cell MDR assay
The control group (HCT-8/VCR cells not treated with
curcumin) and the experimental group (HCT-8/VCR cells
treated with 25 mM curcumin for 24 h) were used. HCT-8/
VCR cells in the logarithmic growth phase were seeded in
96-well plates at a density of 36103 cells per well, incubated
for 24 h, and treated with increasing concentrations of VCR,
DDP, 5-FU, and HCPT based on the plasma peak
concentration obtained during chemotherapy. After incuba-
tion for 72 h, 20 ml of MTT (5 mg/ml in PBS) was added to
each well, and the cells were incubated at 37 C˚ for 4 h. Then,
150 ml of DMSO was added to each well to stop the reaction.
The absorbance at 570 nm was measured to determine the
growth inhibition in each well. The IC50 values were
determined using Bliss software(DAS 2.0,Mathematical
Pharmacology Professional Committee of China, Shanghai,
China). The reversal fold (RF) was calculated.
Efflux and accumulation of Rh123 was measured by
flow cytometry
For determination of Rh123 efflux, cells were loaded for
60 min with Rh123 in the absence of curcumin, and then the
medium was replaced with Rh123-free medium containing
curcumin or the vehicle (DMSO). Following efflux intervals
of 60 min, the medium was removed, and the cells were
washed twice with ice-cold Hanks’ balanced salt solution
(HBSS) and placed in HBSS containing 10% fetal bovine
serum on wet ice. The green fluorescence of Rh123 was
measured using a FACScan flow cytometer.
The measurement of Rh123 accumulation was performed
as previously described (10). Briefly, cells (56105 per
sample) were incubated in the dark with 1 mg/ml Rh123
at 37 C˚ in 5% CO2 for 2 h. Curcumin (25 mM, dissolved in
0.1% DMSO) was added to the cells at the same time as the
Rh123. Following Rh123 accumulation, the cells were
washed twice with ice-cold HBSS and prepared for flow
cytometry as described above.
RT-PCR analysis
Total RNA from cells and snap-frozen tumor samples was
isolated using TRIzol, as recommended by the manufac-
turer. RT-PCR was used for the analysis of multidrug
resistance gene (MDR1) and survivin mRNA with GAPDH
as an internal control. Primers for MDR1 were as follows:
forward primer 59-CAAGGAAGCCAATGCCTATGAC-39,
reverse primer 59-ATCCAGAGCCACCTGAACCACT-39.
Survivin mRNA primers were as follows: forward 59-
GACCACCGCATCTCTACATTC-39 and reverse 59-GTTCT-
TGGCTCTTTCTCTGTCC-39. GAPDH primers were as
follows: forward 59-ACCACAGTCCATGCCATCAC-39 and
reverse 59-TCCACCACCCTGTTGCTGTA-39. The reactions
were performed in accordance with standard protocols.
PCR was performed by an initial denaturation at 94 C˚ for
5 min followed by 30 cycles of 94 C˚ for 30 s, 58 C˚ for 30 s,
and 72 C˚ for 60 s. The products were separated by
electrophoresis in 2% agarose and visualized using ethi-
dium bromide. The experiments were performed in
triplicate.
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Western blot analysis
The cells were either treated with curcumin or left untreated
(control) and incubated for 48 h. Next, they were harvested,
lysed in lysis buffer containing 150 mMsodium chloride, 0.1 M
Tris, 1% Tween-20, 50 mM diethyldithiocarbamic acid, 1 mM
ethylenediamine tetraacetic acid, and protease inhibitors at pH
8.0. The lysates were centrifuged at 12,500 rpm at 4 C˚ for
15 min, and the supernatants were collected. The protein
extracts were separated by sodium dodecyl sulfate-polyacdene
gel electrophoresis and transferred onto nitrocellulose mem-
branes. The membranes were then blocked with rabbit anti-
survivin, anti-P-gp, and anti-b-actin primary polyclonal anti-
bodies, respectively, at 4 C˚ overnight. After washing with PBS
containing 0.05% Tween 20, the membranes were incubated
with the secondary antibody (goat anti-rabbit) for 2 h. Then,
they were visualized using chemiluminescence detection
reagents according to the manufacturer’s instructions.
Animal studies
Five-week-old, female BALB/C nude mice were obtained
from the Laboratory Animal Center of Chongqing Medical
University. They were maintained in a specific pathogen-free
unit under isothermal conditions. All of the experimental
procedures were conducted in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals. HCT-8/VCR cells (46106) suspended in 0.1 ml of
PBS were implanted subcutaneously into the right flank of
nude mice to form xenograft tumors. When the tumor size
reached approximately 100 mm3, the mice were randomly
divided into four groups with five mice in each group.
Curcumin (50 mg/kg) and VCR (2 mg/kg) were adminis-
tered twice daily by peritumoral injections for 14 days. The
tumors were monitored by measuring the tumor volume with
vernier calipers. The volumewas calculated using the formula:
V (mm3) = length6width2/2. After 14 days, the tumors were
harvested for western blot and RT-PCR analysis. In addition,
each tumor was fixed in 4% formaldehyde, dehydrated,
paraffin-embedded, sectioned, and stained with hematoxylin-
eosin to observe changes in pathological cell morphology in
the different groups using a light microscope.
P-gp and survivin protein expression in xenograft
tumors
Snap-frozen tumor samples were mechanically homoge-
nized in the lysis buffer, and the lysates were collected by
centrifugation as described above. The following steps were
the same as described above for the western blot analysis.
Statistical analysis
All data were displayed as the mean ¡ standard
deviation (SD), analyzed by analysis of variance (ANOVA)
and Student’s t-test as appropriate, and processed using the
statistical software SPSS 13.0. Differences were considered
significant at p,0.05. All experiments were repeated in
triplicate.
& RESULTS
Concentration of curcumin
After HCT-8/VCR cells were treated with increasing
concentrations of curcumin, cell growth was inhibited to
different degrees. There was no significant toxicity observed
in cells treated with curcumin at a concentration of 25 mM or
less; at concentrations greater than 25 mM, concentration-
dependent cell toxicity was observed (Figure 1A). Therefore,
25 mM curcumin was selected as the maximum curcumin
concentration for the experiments.
Influence of curcumin on cellular growth
When different concentrations of curcumin (6.25, 12.5,
and 25 mM) were applied to the colon cancer cell line HCT-
8/VCR, the MTT assays showed that with increasing
concentrations of curcumin and longer incubation times,
the inhibition of cellular growth also increased, and the
inhibition of cell growth by curcumin was significantly
greater than the inhibition mediated by VCR (0.5 mg/ml)
(Figure 1B) (p,0.05).
Curcumin-mediated reversal of MDR in HCT-8/VCR
cells
From the MTT assay, the IC50 values of VCR, DDP, 5-FU,
and HCPT were calculated to be 62.3¡1.2 mg/ml,
47.9¡3.6 mg/ml, 13.4¡1.3 mg/ml, and 34.2¡2.1 mg/ml,
respectively, in HCT-8/VCR cells. In HCT-8/VCR cells
treated with 25 mM curcumin for 24 h, the sensitivity of
HCT-8/VCR to VCR, DDP, 5-FU, and HCPT was enhanced,
and the IC50 values were significantly decreased, with
values of 13.6¡0.9 mg/ml, 16.1¡1.7 mg/ml, 8.3¡0.8 mg/ml,
and 29.7¡1.8 mg/ml, respectively (p,0.05). The RF values
were 4.6, 3.0, 1.6, and 1.2 times, respectively (Table 1).
Figure 1 - Suppression of HCT-8/VCR cell growth by curcumin treatment. A) Concentration-response curves in HCT-8/VCR cells treated
with different concentrations of curcumin. Curcumin inhibited the growth of HCT-8/VCR cells in a concentration-dependent manner
(mean¡ SD, n=3). B) The effects of curcumin on HCT-8/VCR cell growth were detected by flow cytometry. The cells were treated with
various curcumin concentrations and 0.5 mg/ml VCR for 6 days. The inhibitory effect of curcumin on cells was significantly higher at
25 mM than at other concentrations (mean¡ SD, n= 3) *p,0.01 vs. control group, #p,0.05 vs. VCR group, p.0.01 vs. control group.
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Efflux and accumulation of Rh123 in HCT-8/VCR
cells
Flow cytometry experiments demonstrated that the efflux
and accumulation of Rh123 in HCT-8/VCR cells treated
with 25 mM curcumin was significantly higher than that in
control cells (p,0.05). As shown in Figure 2, the fluores-
cence intensity of the group treated with curcumin was
significantly higher than that of the negative control group.
These results indicate that curcumin inhibits the efflux of P-
gp, thereby increasing the accumulation of drugs in MDR
cells.
Inhibition of MDR1 gene expression
As shown by RT-PCR assays (Figure 3aA), curcumin
significantly suppressed the expression of MDR1 mRNA in
HCT-8/VCR cells. P-gp protein expression analyzed by
western blotting was consistent with the RT-PCR results
(Figure 3aB).
Effects of curcumin on an in vivo xenograft tumor
model
After 14 days of treatment, xenografted mice were
sacrificed and the tumors were resected. The PBS-treated
group had larger tumors than the other groups (volume of
7,033.00 mm3). The mean tumor volume of the group
treated with a combination of curcumin and VCR was
402.3 mm3, which was much smaller than that of the VCR-
treated group (1338.4 mm3), the curcumin-treated group
(782.5 mm3), and the PBS-treated group (Table 2, Figure 4A).
Morphology of xenograft tumors
Light microscopy revealed that the tumor cells in the
control group were round, oval, polygonal, and large, and
they had hyperchromatic nuclei, larger nuclear slurry ratios,
more caryokinesis, more heterogeneity, less karyopyknosis,
fewer lymphocytes, and less necrosis than the tumor cells in
the curcumin group and the curcumin plus VCR group
(Figure 4C).
RT-PCR analysis of MDR1 and survivin mRNA in
xenograft tumors
To determine the effects of curcumin on MDR1 and
survivin mRNA expression in vitro, we analyzed MDR1 and
survivin mRNA levels in tumors using RT-PCR. As shown
in Figure 3bAB, RT-PCR demonstrated that curcumin
significantly suppressed the expression of MDR1 and
survivin mRNA in the xenograft tumors. The combination
of VCR and curcumin suppressed the expression of MDR1
and survivin mRNA to a greater extent, whereas VCR
produced little inhibition of MDR1 and survivin mRNA
expression.
Western blot analysis of P-gp and survivin in
xenograft tumors
To determine the effect of curcumin on P-gp and survivin
protein expression in vivo we analyzed P-gp and survivin
protein expression in tumors by western blot analysis. As
shown in Figure 3bC, curcumin and the combination of
curcumin and VCR in xenograft tumors significantly
decreased the expression of P-gp and survivin protein. In
contrast, VCR had little effect on survivin expression.
Table 1 - Reversal of multidrug-resistance in the colon
cancer cell line HCT-8/VCR by curcumin (mean ¡ SD,
n=3).
Drugs IC50 (mg/ml) RF
HCT-8/VCR HCT-8/VCR+curcumin
VCR 62.3¡1.2 13.6¡0.9* 4.6
DDP 47.9¡3.6 16.1¡1.7* 3.0
5-FU 13.4¡1.3 8.3¡0.8* 1.6
HCPT 34.2¡2.1 29.7¡1.8* 1.2
*p,0.05 vs. HCT-8/VCR, RF = reversal fold.
Figure 2 - Effects of curcumin on Rh123 retention (a) and accumulation (b) in HCT-8/VCR cells. a. The cells were incubated with Rh123
for 60 min, washed, and resuspended in medium with 10 mM curcumin or the vehicle control (0.1% DMSO) for 60 min. Rh123
fluorescence was measured using FACScan. b. The cells were treated with 25 mM curcumin or the vehicle control (0.1% DMSO). Rh123
(1 mg/ml) was added, and the cells were incubated for 120 min. Rh123 fluorescence was measured using flow cytometry. Data are
presented as the mean ¡ SD (n=3). A: Blank control group; B: Negative control group; C: Curcumin group. The mean fluorescence
intensity of the curcumin group was significantly higher than that of the negative control group. p,0.01 vs. negative control group.
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& DISCUSSION
Colorectal carcinoma (CRC) is the most frequent malig-
nancy of the alimentary system and accounts for approxi-
mately 40% of new cancer cases of the digestive tract (11).
With increasing social and economic development and
changes in lifestyle and diet, the incidence of CRC has
increased annually. Currently, CRC treatment is surgery-
based and supplemented by comprehensive treatments
based on chemotherapy, radiation therapy, and Chinese
medicine. Chemotherapy plays an important role in the
comprehensive treatment of CRC, but MDR tumors are
resistant to chemotherapy. There is an urgent need to
establish an effective modality for overcoming MDR.
MDR is the major cause for the reduced effects of
chemotherapy on tumors. It is necessary to find a strong
agent with minimal side effects that can reverse the effects
of MDR to improve the effect of chemotherapy on MDR
tumors. Kuttan et al. (12) first raised the possibility of anti-
tumor activity for turmeric and curcumin, as they initially
showed that turmeric extract and curcumin reduced the
development of animal tumors. Subsequent studies have
shown that the inhibitory mechanism of curcumin on tumors
is related to the induction of tumor cell apoptosis and the
inhibition of tumor angiogenesis and invasion andmetastasis
of tumor cells. Anuchapreeda et al. found that curcumin
decreased the MDR1 mRNA level in patient leukemic cells,
especially in those with a high level of theMDR1 gene (13). In
addition, Hui et al. (14) found that curcumin reversed the
MDR of the melphalan-resistant multiple myeloma cell line
MOLP-2/R by inhibiting the FA/BRCA pathway. A short
treatment with curcumin induced DNA damage, decreased
cell viability, and triggered apoptosis in MDR K562/A02
cells, and Cu2+ enhanced curcumin-mediated apoptosis
through the generation of reactive oxygen species (15). The
treatment of drug-resistant human cervical carcinoma KBV1
cells with curcumin increased their sensitivity to vinblastine,
which was consistent with downregulation of the MDR-1
gene product, P-gp, on the cell plasma membrane (16).
Curcumin (1–10 mM)was shown to decrease P-gp expression
and reduced P-gp-mediated efflux in drug-resistant human
cervical carcinoma cells (KBV1). Curcuminwas also shown to
increase Rh123 accumulation in a concentration-dependent
manner (1–55 mM) and inhibit the efflux of Rh123 from these
Figure 3 - Inhibition of the expression of MDR1 mRNA and P-gp and survivin mRNA and protein in HCT-8/VCR cells and xenograft
tumors. A and B, MDR1 mRNA and P-gp protein expression in HCT-8/VCR cells. 1: control group, 2: curcumin group. RT-PCR showed
significant reduction of MDR1 mRNA in curcumin-treated cells. P-gp protein levels detected by western blotting in the above-
mentioned groups were consistent with the mRNA expression levels. C, D and E, MDR1 mRNA and P-gp and survivin mRNA and protein
expression in xenograft tumors. 1: control group; 2: VCR group; 3: curcumin group; 4: curcumin+VCR group. (C) and (D): RT-PCR showed
significant reduction of survivin mRNA and MDR1 mRNA in tumors treated with curcumin or curcumin+VCR. (E) Survivin and P-gp
protein levels determined by western blotting in the above-mentioned groups were consistent with the mRNA expression levels. *: vs.
control group, p,0.05, #: vs. curcumin group, p,0.05.
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cells (17). Furthermore, curcumin was shown to sensitize
human colorectal cancer to capecitabine through modulation
of the expression of cyclin D1, cyclooxygenase-2 (COX-2),
matrix metalloproteinases (MMP-9), vascular endothelial
growth factor (VEGF), and C-X-C chemokine receptor type
4 (CXCR4) in an orthotopic mouse model (18). These findings
suggest that curcuminmay represent a new reversal agent for
the chemosensitization of cancer cells.
In our study, the treatment of HCT-8/VCR cells with 6.25,
12.5, 25, 50, or 100 mM curcumin inhibited the growth of the
Table 2 - Effects of curcumin and VCR on the weight and volume of HCT-8/VCR tumors in nude mice and the inhibition
rates of tumors (mean ¡ SD).
Group Mean tumor weight (g) Inhibition rate of tumors Mean volume (mm
3)
Before intervention 14 days after intervention
A 1.21¡0.25 / 98.2¡34.5 1406.6¡128.3
B 1.13¡0.27 9.3% 106.1¡39.3 1338.4¡109.5
C 0.75¡0.27 39.1% 102.3¡41.5 782.5¡109.2 * #
D 0.42¡0.23 65.3% 103.5¡40.8 402.3¡58.4 * # q
*vs. control group, p,0.01;
#vs. VCR group, p,0.05;
qvs. curcumin group, p,0.05.
A: control group; B: VCR group; C: curcumin group; D: curcumin+VCR group.
Figure 4 - Effect of curcumin on MDR in a HCT-8/VCR nude mice xenograft tumor model. Five-week-old female BALB/C nude mice were
injected subcutaneously with HCT-8/VCR cells. Curcumin (50 mg/kg) and VCR (2 mg/kg) were administered twice daily through
peritumoral injections for 14 days. After two weeks, the mice were sacrificed, and the tumors were harvested. A: control group; B: VCR
group; C: curcumin group; D: curcumin+VCR group. (a) Effect of curcumin on the growth of HCT-8/VCR cells xenografted in nude mice,
showing that curcumin inhibited tumor growth. (b) Representative tumor formation 14 days after intervention. (c) Hematoxylin-eosin
staining of the tumors. (HE staining,6200) A: control group; B: VCR group; C: curcumin group; D: curcumin+VCR group. The insets
show magnified images representing typical changes of the tumor tissue.
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cells in a concentration-dependent manner. It is assumed
that curcumin induced apoptosis or necrosis of the cells;
however, determination of the specific mechanism requires
further investigation. Curcumin significantly increased the
sensitivity of HCT-8/VCR cells to VCR, DDP, 5-FU, and
HCPT. In an animal model, we demonstrated that curcumin
inhibits xenograft growth. Cotreatment of curcumin and
VCR significantly inhibited xenograft growth, showing a
synergistic effect.
The mechanism of MDR formation is complex. P-gp-
mediated MDR is considered to be the classic mechanism of
resistance. P-gp is an ATP-dependent membrane transport
protein encoded by the MDR1 gene, and it pumps
exogenous cell substances from the inside to the outside of
cells to protect tissues from exogenous toxic substances
(19,20). In the MDR phenotype of tumors, P-gp can pump
hydrophobic pro-lipid anti-cancer drugs out of cells, reduce
the intracellular drug concentration, and cause MDR (21).
Various studies have shown that the MDR of tumor cells can
be reversed by inhibition of P-gp expression and function,
which restores their sensitivity to chemotherapeutic drugs
(22,23). Rh123 is a substrate of P-gp, which pumps Rh123
out of the cell to decrease the intracellular concentration.
The accumulation or efflux of Rh123 in tumor cells can be
used to assess the function of P-gp (24).
In the present study, we found that curcumin signifi-
cantly increased the accumulation and retention of Rh123 in
the colon cancer cell line HCT-8/VCR and reduced the
efflux of Rh123. We speculated that curcumin could inhibit
the drug transport function of P-gp to regulate the
intracellular content of Rh123. The MTT assay showed that
curcumin enhanced the sensitivity of HCT-8/VCR cells to a
variety of chemotherapeutic drugs to reverse their MDR by
inhibiting the transport function of P-gp so that the drugs
could enter the cells. In the RT-PCR and western blot
experiments, curcumin (25 mM)-treated cells had signifi-
cantly lower levels of MDR1 gene and P-gp protein
expression after treatment. In animal models, we demon-
strated expression of the MDR1 gene and P-gp protein in
xenografts treated with curcumin was lower than that in the
control group and the VCR group. Expression of the MDR1
gene and the P-gp protein in xenografts that were cotreated
with curcumin and VCR was lower than that in xenografts
treated with curcumin alone. These results suggest that
curcumin inhibited P-gp pump function and reduced the
expression of P-gp protein, thereby reducing intracellular
drug efflux, increasing the intracellular drug concentration,
and enhancing the sensitivity of resistant cells to the
chemotherapeutic drug. Thus, curcumin could partially
reverse MDR.
Survivin is a regulator of apoptosis that may participate in
cancer development (25,26), and it blocks apoptosis induced
by a variety of nonrelated apoptosis triggers, including
various anti-tumor agents (27-29). It has been reported that
survivin is involved in chemotherapy resistance (30,31) and
may serve as a radio- and chemo-resistance factor (32).
Studies have shown that survivin expression is significantly
higher in various cancer cells after treatment with anti-
cancer drugs (33,34); therefore, survivin may potentially
play a key role in resistance to anti-cancer drugs. In our
study, we demonstrated that expression of the survivin gene
and protein in xenografts treated with curcumin was lower
than that in the control group and the VCR group, as shown
by RT-PCR and western blot assays. Expression of the
survivin gene and protein in xenografts that were cotreated
with curcumin and VCR was lower than that in xenografts
treated with curcumin alone. The mRNA and protein levels
of survivin were decreased, which resulted in a decline in
the anti-apoptotic function of survivin. Induction of tumor
cell apoptosis or decreased survivin levels may decrease the
turnover of P-gp or transport by P-gp in cells, thereby
blocking the mechanism of resistance of tumor cells and
reversing drug resistance.
In summary, curcumin reversed the MDR of tumor cells
in vitro and in vivo. Despite these encouraging results, this
study was limited in that it does not explain the specific
mechanism underlying the effect of curcumin on P-gp and
survivin and the relationship between P-gp and survivin in
colon cancer. However, our results suggest that curcumin
could be a promising chemosensitizer to counteract MDR in
colon cancer.
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